MET and renal cell carcinoma: Cabozantinib is an inhibitor of receptor tyrosine kinases including VEGFR2, and the tyrosine kinases MET (hepatocyte growth factor receptor) and AXL (GAS6 receptor) implicated in development of resistance to RCC therapy [8–10].